YU39899A - Polimorf zopolrestat monohidrata - Google Patents
Polimorf zopolrestat monohidrataInfo
- Publication number
- YU39899A YU39899A YU39899A YU39899A YU39899A YU 39899 A YU39899 A YU 39899A YU 39899 A YU39899 A YU 39899A YU 39899 A YU39899 A YU 39899A YU 39899 A YU39899 A YU 39899A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- zopolrestat
- diabetic
- monohydrate
- refers
- polymorph
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Ovaj pronalazak se odnosi na zopoirestat monohidrat i njegove polimorfe. Ovaj pronalazak se takodje odnosi na postupke dobijanja zopolrestat monohidrata, dobijanja njegovih polimorfa i dobijanja anhidrovanog zopolrestata. Ovaj pronalazak se takodje odnosi na kompozicije koje uključuju zopolrestat monohidrat i metode upotrebe zopolrestat monohidrata i njegovih kompozicija radi tretiranja dijabetičnih komplikacija kao što je dijabetična katarakta, dijabetična retinopatija ili dijabetična neuropatija, snižavanje nivoa lipida u krvi ili nivoa mokraćne kiseline u krvi.[This invention refers to zopolrestat monohydrate and its polymorphs. This invention also refers to the procedure for obtaining zopolrestat monohydrates, obtainin their polymorphs and obtaining unhydrate zopolrestat. This invention also refers to compositions that include zopolrestat monohydrate and methods of using zopolrestat monohydrate and its compositions for the treatment of diabetic complications such as diabetic complictions like diabetic cataract, diabetic reinotherapy or diabetic neuropaty, lowering the level of lipides in the blood or level of urea acid in the blood.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9747498P | 1998-08-21 | 1998-08-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| YU39899A true YU39899A (sh) | 2002-12-10 |
Family
ID=22263562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU39899A YU39899A (sh) | 1998-08-21 | 1999-08-19 | Polimorf zopolrestat monohidrata |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US6159976A (sh) |
| EP (1) | EP0982306A3 (sh) |
| JP (1) | JP2000072769A (sh) |
| KR (1) | KR20000017411A (sh) |
| CN (1) | CN1245804A (sh) |
| AP (1) | AP9901662A0 (sh) |
| AU (1) | AU4453299A (sh) |
| BG (1) | BG103674A (sh) |
| BR (1) | BR9903873A (sh) |
| CA (1) | CA2280590A1 (sh) |
| EA (1) | EA199900675A3 (sh) |
| EE (1) | EE9900385A (sh) |
| GT (1) | GT199900137A (sh) |
| HR (1) | HRP990259A2 (sh) |
| HU (1) | HUP9902783A3 (sh) |
| ID (1) | ID23307A (sh) |
| IL (1) | IL131419A0 (sh) |
| IS (1) | IS5155A (sh) |
| MA (1) | MA26678A1 (sh) |
| NO (1) | NO994027L (sh) |
| NZ (1) | NZ337363A (sh) |
| OA (1) | OA11150A (sh) |
| PA (1) | PA8480601A1 (sh) |
| PE (1) | PE20000993A1 (sh) |
| PL (1) | PL335016A1 (sh) |
| SG (1) | SG83147A1 (sh) |
| TN (1) | TNSN99159A1 (sh) |
| TR (1) | TR199901996A2 (sh) |
| UY (1) | UY25668A1 (sh) |
| YU (1) | YU39899A (sh) |
| ZA (1) | ZA995297B (sh) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS63796B1 (sr) | 2010-07-16 | 2022-12-30 | Univ Columbia | Inhibitori aldoza reduktaze i njihova upotreba |
| US8916563B2 (en) | 2010-07-16 | 2014-12-23 | The Trustees Of Columbia University In The City Of New York | Aldose reductase inhibitors and uses thereof |
| WO2014126885A1 (en) * | 2013-02-13 | 2014-08-21 | Mylari Banavara L | Water soluble salts of aldose reductase inhibitors for treatment of diabetic complications |
| DK3757107T3 (da) | 2016-06-21 | 2023-11-27 | Univ Columbia | 4-oxo-3,4-dihydrothieno[3,4-d]pyridazinforbindelser som aldosereduktasehæmmere og metoder til anvendelse deraf |
| CA3071114A1 (en) | 2017-07-28 | 2019-01-31 | Applied Therapeutics Inc. | Compositions and methods for treating galactosemia |
| SG11202110590PA (en) | 2019-04-01 | 2021-10-28 | Applied Therapeutics Inc | Inhibitors of aldose reductase |
| EP4125909A1 (en) | 2020-03-31 | 2023-02-08 | Applied Therapeutics Inc. | Aldose reductase inhibitors for the treatment of acute respiratory distress syndrome, acute lung inflammation/injury, cardiac injury and anti-viral therapy |
| CA3176768A1 (en) | 2020-05-01 | 2021-11-04 | Shoshana SHENDELMAN | Aldose reductase inhibitors for treating sorbitol dehydrogenase deficiency |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4748280A (en) * | 1985-11-07 | 1988-05-31 | Pfizer Inc. | Certain chlorination process for preparing 2-chloro-1,1,1-(C1 -C6) |
| US4939140A (en) * | 1985-11-07 | 1990-07-03 | Pfizer Inc. | Heterocyclic oxophthalazinyl acetic acids |
| US4868301A (en) * | 1987-06-09 | 1989-09-19 | Pfizer Inc. | Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains |
| JPH0676391B2 (ja) * | 1987-06-09 | 1994-09-28 | フアイザー・インコーポレイテツド | ベンゾチアゾール等の複素環側鎖を有するオキソフタラジニル酢酸類の製造方法 |
| US4904782A (en) * | 1988-02-29 | 1990-02-27 | Pfizer Inc. | Process for the production of phthalazineacetic acid ester derivatives and a novel intermediate |
| US4954629A (en) * | 1989-05-11 | 1990-09-04 | Pfizer Inc. | Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof |
| WO1992003432A1 (en) * | 1990-08-28 | 1992-03-05 | Pfizer Inc. | 3-(5-trifluoromethylbenzothiazol-2-ylmethyl)-4-oxo-3h-phythalazin-1-ylacetic acid monohydrate |
| US5391551A (en) * | 1993-05-10 | 1995-02-21 | Pfizer Inc. | Method of lowering blood lipid levels |
| US6127367A (en) * | 1996-02-29 | 2000-10-03 | Pfizer, Inc. | Method of reducing tissue damage associated with non-cardiac ischemia |
-
1999
- 1999-08-06 EP EP99306252A patent/EP0982306A3/en not_active Withdrawn
- 1999-08-13 US US09/374,729 patent/US6159976A/en not_active Expired - Fee Related
- 1999-08-16 IL IL13141999A patent/IL131419A0/xx unknown
- 1999-08-17 IS IS5155A patent/IS5155A/is unknown
- 1999-08-17 AU AU44532/99A patent/AU4453299A/en not_active Abandoned
- 1999-08-18 TN TNTNSN99159A patent/TNSN99159A1/fr unknown
- 1999-08-18 MA MA25738A patent/MA26678A1/fr unknown
- 1999-08-19 UY UY25668A patent/UY25668A1/es not_active Application Discontinuation
- 1999-08-19 HU HU9902783A patent/HUP9902783A3/hu unknown
- 1999-08-19 YU YU39899A patent/YU39899A/sh unknown
- 1999-08-19 SG SG9904131A patent/SG83147A1/en unknown
- 1999-08-19 OA OA9900185A patent/OA11150A/en unknown
- 1999-08-19 CA CA002280590A patent/CA2280590A1/en not_active Abandoned
- 1999-08-19 GT GT199900137A patent/GT199900137A/es unknown
- 1999-08-19 ZA ZA9905297A patent/ZA995297B/xx unknown
- 1999-08-19 AP APAP/P/1999/001662A patent/AP9901662A0/en unknown
- 1999-08-19 EE EEP199900385A patent/EE9900385A/xx unknown
- 1999-08-20 ID IDP990796A patent/ID23307A/id unknown
- 1999-08-20 EA EA199900675A patent/EA199900675A3/ru unknown
- 1999-08-20 BR BR9903873-0A patent/BR9903873A/pt not_active Application Discontinuation
- 1999-08-20 PA PA19998480601A patent/PA8480601A1/es unknown
- 1999-08-20 TR TR1999/01996A patent/TR199901996A2/xx unknown
- 1999-08-20 PL PL99335016A patent/PL335016A1/xx not_active Application Discontinuation
- 1999-08-20 PE PE1999000844A patent/PE20000993A1/es not_active Application Discontinuation
- 1999-08-20 NZ NZ337363A patent/NZ337363A/xx unknown
- 1999-08-20 KR KR1019990034527A patent/KR20000017411A/ko not_active Application Discontinuation
- 1999-08-20 NO NO994027A patent/NO994027L/no not_active Application Discontinuation
- 1999-08-20 HR HR990259A patent/HRP990259A2/hr not_active Application Discontinuation
- 1999-08-20 BG BG103674A patent/BG103674A/xx unknown
- 1999-08-23 CN CN99118068A patent/CN1245804A/zh active Pending
- 1999-08-23 JP JP11235855A patent/JP2000072769A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EA199900675A3 (ru) | 2000-06-26 |
| JP2000072769A (ja) | 2000-03-07 |
| ZA995297B (en) | 2001-02-19 |
| SG83147A1 (en) | 2001-09-18 |
| BR9903873A (pt) | 2000-09-19 |
| NO994027D0 (no) | 1999-08-20 |
| IL131419A0 (en) | 2001-01-28 |
| HRP990259A2 (en) | 2000-06-30 |
| HU9902783D0 (en) | 1999-10-28 |
| TR199901996A2 (xx) | 2000-03-21 |
| EE9900385A (et) | 2000-04-17 |
| PE20000993A1 (es) | 2000-10-04 |
| HUP9902783A2 (hu) | 2000-12-28 |
| GT199900137A (es) | 2001-02-09 |
| CA2280590A1 (en) | 2000-02-21 |
| PA8480601A1 (es) | 2000-09-29 |
| AP9901662A0 (en) | 1999-09-30 |
| AU4453299A (en) | 2000-03-09 |
| CN1245804A (zh) | 2000-03-01 |
| US6159976A (en) | 2000-12-12 |
| HUP9902783A3 (en) | 2001-01-29 |
| ID23307A (id) | 2000-04-05 |
| KR20000017411A (ko) | 2000-03-25 |
| EP0982306A2 (en) | 2000-03-01 |
| OA11150A (en) | 2003-04-16 |
| BG103674A (en) | 2000-03-31 |
| UY25668A1 (es) | 2001-08-27 |
| EP0982306A3 (en) | 2000-07-05 |
| PL335016A1 (en) | 2000-02-28 |
| TNSN99159A1 (fr) | 2005-11-10 |
| NZ337363A (en) | 2001-01-26 |
| EA199900675A2 (ru) | 2000-02-28 |
| IS5155A (is) | 2000-02-22 |
| MA26678A1 (fr) | 2004-12-20 |
| NO994027L (no) | 2000-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL183953A (en) | Method of reducing oxidant induced damage of a food product, a pharmaceutical or stored blood and novel compounds therefor | |
| WO2004043954A3 (en) | Trans-9,10-dehydroepothilone c and d, analogs thereof and methos of making the same | |
| WO2003022852A3 (en) | Furo-and thienopyrimidine derivatives as angiogenesis inhibitors | |
| PL346520A1 (en) | Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase | |
| WO2005014035A3 (en) | Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest | |
| WO2002060955A3 (en) | Modified antibodies and methods of use | |
| WO2002074337A8 (en) | Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases | |
| WO1999038877A3 (en) | 2-(PURIN-9-yl)-TETRAHYDROFURAN-3,4-DIOL DERIVATIVES | |
| WO2004108139A3 (en) | Use of fused heterocyclic compounds as scce inhibitors for the treatment of skin conditions or cancer | |
| WO2006023704A3 (en) | Lonidamine analogues and their use in male contraception and cancer treatment | |
| WO2001066553A3 (en) | Novel aryl fructose-1,6-bisphosphatase inhibitors | |
| WO2000023407A3 (en) | Ureido-thiobutyric acid derivatives as ppar-agonists | |
| ZA979961B (en) | 5-HT1F agonists | |
| YU39899A (sh) | Polimorf zopolrestat monohidrata | |
| WO2003017939A3 (en) | Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment | |
| ZA200003768B (en) | Methods and compositions for treating diseases and conditions of the eye. | |
| EP1532131A4 (en) | COMPOUNDS OF THE MOTILID TYPE | |
| HK1093016A1 (en) | Use of alpha-ketoglutaric acid for the treatment of malnutrition or high plasma glucose condition | |
| MXPA02000680A (es) | Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf. | |
| WO2002056832A3 (en) | Methods to treat autoimmune and inflammatory conditions | |
| WO2000040232A3 (en) | Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions | |
| WO2000071716A3 (en) | Vascular endothelial growth factor dimers | |
| IL135634A0 (en) | 5-htif agonists | |
| WO1999058098A3 (en) | HUMAN ANTITHROMBIN IIIs AND METHODS RELATED THERETO | |
| WO2001051489A3 (en) | Methods for lowering uric acid levels |